GSK (GSK) J.P. Morgan UK Leaders Conference summary
Event summary combining transcript, slides, and related documents.
J.P. Morgan UK Leaders Conference summary
17 Nov, 2026R&D investment and growth outlook
Accelerate Growth, announced in July, targets GBP 1.9bn in savings to fund R&D acceleration; 22 Phase III starts are expected by year-end 2026, versus ~7 last year and ~6 the year before.
Over five years, sales rose >8%, profit >13% and margin >500 bps, while R&D increased from a teen percentage of sales to just over 20%.
2031 sales target remains >GBP 40bn, risk-adjusted for technical and regulatory success; oncology is the largest gap versus consensus, with B7-H3 and six launch-stage or near-approval products potential catalysts over the next 2–3 years.
Consensus 2031 sales estimates have risen from ~GBP 33bn to GBP 36.6bn; 2030 consensus margins have moved from 25% to 30%.
Savings and operating model
The GBP 1.9bn savings target is set for 2029, with 90% expected by 2028; delivery is potentially ahead of schedule, led by support-function streamlining, supply-chain changes, technology and AI.
Savings are intended primarily to accelerate R&D; through dolutegravir patent expiry in 2028–2030, margins are expected to remain stable or improve, with flexibility to retain savings for investment or let them flow through.
AI is being applied to field-force coaching and marketing-mix simulations, as well as target searches, patient and trial-site identification, vaccine-trial placement and organoid development; management described faster R&D workflows.
Business development and financial capacity
Business development priorities are oncology and respiratory immunology and inflammation, with more limited vaccine opportunities; focus is on validated mechanisms addressing unmet need, including efficacy or tolerability gaps.
Net debt to EBITDA was 1.8x pro forma at September-end, versus ~1.3x last year; further deals remain possible, typically in the $2bn–$4bn range, while cash generated from operations is guided above GBP 10bn this year at prior-year exchange rates.
Nuvalent assets Jemperli and neladalkib target non-small cell lung cancer; Jemperli first-line filing is expected by year-end, while neladalkib’s PDUFA date was set for November 27 and first-line opportunity is several years out.
Latest events from GSK
- Four- and six-month HIV regimens, pipeline launches and oncology aim to sustain growth through expiries.GSK
Jefferies Global Healthcare Conference - Biomarker-led R&D advances long-acting airway therapies and novel liver programs.GSK
3rd Annual Guggenheim Healthcare Innovation Conference - Specialty-led growth and pipeline investment support reaffirmed FY26 guidance.GSK
Q3 2026 - Oncology data highlighted gains across ADCs, immunotherapy and targeted therapies.GSK
ESMO 2026 Investor Briefing - 14% CER sales growth and upgraded outlooks to >£38bn sales by 2031.GSK
Q4 2023 - Ultra-long-acting biologics, AI-driven R&D, and global partnerships are shaping future growth.GSK
Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum - GBP 1.9bn in savings will fund pipeline growth, with oncology and specialty assets prioritized.GSK
Bank of America Global Healthcare Conference - Rapid portfolio growth and robust clinical data position oncology for major advances by 2031.GSK
Morgan Stanley 24th Annual Global Healthcare Conference - Accelerated R&D, pipeline reinvestment, and specialty focus drive growth and margin stability.GSK
Bernstein’s 23rd Annual Pan-European Strategic Decisions Conference